Practice

Biosimilars, Interchangeability, and Perceptions of Safety

October 30th 2017

Interchangeability and Rheumatology Prescribing Practices

October 30th 2017

Biosimilar Interchangeability and Market Share

October 30th 2017

Infographic: Anticancer Drug Costs on the Rise

October 29th 2017

By The Center for Biosimilars Staff

A recent study found that injectable anticancer drugs steadily increase in price, even after competition enters the market.

Risankizumab Outperforms Humira, Stelara in Treating Plaque Psoriasis

October 27th 2017

By Jackie Syrop

As AbbVie’s best-selling Humira faces oncoming biosimilar competition, the drug maker is developing a new innovator product that could help it retain a hold on the market; new results from 3 phase 3 clinical trials show AbbVie’s investigational interleukin-23 inhibitor, risankizumab, to be more effective than adalimumab (Humira) or ustekinumab (Stelara) in patients with moderate-to-severe plaque psoriasis.

FDA Launches New Educational Materials on Biosimilar Therapies

October 24th 2017

By Kelly Davio

The FDA has released a new set of educational materials concerning the nature and the prescribing of biosimilar therapies.

Consensus Recommendations on Pegfilgrastim for Prophylaxis of Febrile Neutropenia

October 23rd 2017

By Kelly Davio

A paper by Matti Aapro, MD, recently published in Supportive Cancer Care, outlined, for the first time, consensus recommendations on using pegfilgrastim in particular patients and therapeutic scenarios.

Long-Term Data Support Switching From Reference Infliximab to SB2

October 21st 2017

By Kelly Davio

New data from an extension period of a phase 3 study of Samsung Bioepis’ SB2 (Renflexis) in patients with moderate to severe rheumatoid arthritis found that there was no clinically meaningful difference in safety, efficacy, or immunogenicity in patients who were switched from reference infliximab to the biosimilar compared with patients who continued treatment with either the reference or the biosimilar without switching.

The Top 5 Biosimilars Articles for the Week of October 16

October 20th 2017

The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of October 16.

Study Reports 24% Discontinuation Rate After Switching From Remicade to Biosimilar CT-P13

October 19th 2017

By Jackie Syrop

A Dutch study reports that 24% of patients who switched from originator infliximab to CT-P13, an infliximab biosimilar, discontinued the biosimilar by their 6-month follow-up, mainly for reasons researchers termed “subjective” health complaints.